Healthcare Sales & Marketing Network News: NS5A

Searching News Database: NS5A

HSMN NewsFeed - 31 Jan 2020
AbbVie Receives Positive CHMP Opinion for MAVIRET(R) (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 Jun 2017
AbbVie Receives CHMP Positive Opinion for MAVIRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Apr 2017
Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 3 Jan 2017
Ascletis Raises US$100 Million in Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 19 Dec 2016
AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Sep 2016
AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 25 Jul 2016
CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 15 Apr 2016
AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
Biopharmaceuticals

HSMN NewsFeed - 15 Apr 2016
AbbVie Announces Real-World Data with VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA(R) (dasabuvir tablets) from Large German Hepatitis C-Registry
Biopharmaceuticals

HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 14 Dec 2015
Enanta Pharmaceuticals Announces the Election of Bruce L.A. Carter, Ph.D. as Non-Executive Chairman of the Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Sep 2015
Ascletis Secures US$35 Million Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 23 Feb 2015
Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi(R) and Harvoni(R) in India
Biopharmaceuticals Distribution

HSMN NewsFeed - 16 Jan 2015
European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals Regulatory

HSMN NewsFeed - 27 Aug 2014
European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection
Biopharmaceuticals Regulatory

HSMN NewsFeed - 27 Jun 2014
Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza(R) (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 10 Apr 2014
Gilead Announces Results from Study of Sovaldi(R) for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy
Biopharmaceuticals

HSMN NewsFeed - 30 Nov 2012
BioCryst Pharmaceuticals and Presidio Pharmaceuticals Mutually Terminate Merger Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 18 Oct 2012
BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 6 Jun 2012
Achillion Announces Resignation of Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 May 2012
Achillion Announces Executive Promotion
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 May 2011
Abbott Receives FDA Approval for Molecular Test for Hepatitis C
Diagnostics FDA

HSMN NewsFeed - 3 Mar 2011
InterMune Receives European Union Approval for Esbriet(R) (pirfenidone)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 Dec 2010
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet (Pirfenidone) in Europe
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Dec 2010
InterMune Announces Positive Opinion for Approval of Esbriet (Pirfenidone) in European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 12 Jan 2010
Eric Ruby Joins Presidio Pharmaceuticals, Inc. as Vice President of Regulatory Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Aug 2009
Dr. Nathaniel Brown Joins Presidio Pharmaceuticals, Inc. as Senior Vice President of Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Feb 2009
Eiger BioPharmaceuticals Raises $7.1 Million 'A' Round
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 20 Mar 2008
Presidio Pharmaceuticals Obtains Exclusive Worldwide Rights to XTL Biopharmaceuticals Ltd. Hepatitis C Virus (HCV) NS5A Program
Biopharmaceuticals Licensing

HSMN NewsFeed - 20 Mar 2008
XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
Biopharmaceuticals Licensing

HSMN NewsFeed - 1 Feb 2007
AstraZeneca Acquires Arrow Therapeutics To Broaden Anti-Infective Capabilities
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 16 Jan 2007
Presidio Pharmaceuticals Receives Exclusive License to Novel Hepatitis C Virus (HCV) Technology from Stanford University
Biopharmaceuticals Licensing

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.